SCHEMBL10205209

SCHEMBL10205209

Cc1cc(C2CCN(C)CC2)ccc1Nc1ncc(Cl)c(NCc2cccc3c2C(C)(C)C(=O)N3)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 5/20 0.47
▸ EGFR P00533 4/20 0.47
▸ INSR P06213 1/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ FLT4 P35916 1/20 0.46
▸ PTK2 Q05397 1/20 0.46
▸ TNK2 Q07912 4/20 0.42
▸ JAK2 O60674 3/20 0.42
▸ SRC P12931 2/20 0.42
▸ JAK3 P52333 4/20 0.41
▸ BTK Q06187 2/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ TTK P33981 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ TXK P42681 1/20 0.41
▸ BLK P51451 1/20 0.41
▸ ITK Q08881 1/20 0.41
▸ NTRK1 P04629 1/20 0.41
▸ NTRK3 Q16288 1/20 0.41
▸ NTRK2 Q16620 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16255604 0.93 FLT4 (0.41) ALKEGFRINSRIGF1RFLT4
SCHEMBL10205190 0.92 EGFR (0.51) ALKEGFRINSRIGF1RFLT4
SCHEMBL10207086 0.92 EGFR (0.41) ALKEGFRINSRIGF1RFLT4
SCHEMBL16255608 0.92 EGFR (0.47) ALKEGFRINSRIGF1RFLT4
SCHEMBL10205508 0.92 FLT4 (0.45) ALKEGFRINSRIGF1RFLT4
SCHEMBL14331699 0.91 EGFR (0.43) ALKEGFRINSRIGF1R
SCHEMBL16255628 0.91 EGFR (0.39) ALKEGFRINSRIGF1RFLT4
SCHEMBL10205507 0.91 EGFR (0.58) ALKEGFRINSRIGF1RTNK2
SCHEMBL10205156 0.91 EGFR (0.47) ALKEGFRINSRIGF1RPTK2
SCHEMBL10205192 0.91 EGFR (0.42) ALKEGFRINSRIGF1RFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 ALK 2575/4885EGFR 1397/4885INSR 1352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback